Intervacc AB Logo

Intervacc AB

Develops recombinant protein-based vaccines for animal health.

IVACC | ST

Overview

Corporate Details

ISIN(s):
SE0009607252 (+1 more)
LEI:
549300OICIVZBBZRNZ64
Country:
Sweden
Address:
Västertorpsvägen 135B, 129 44 Hägersten

Description

Intervacc AB is a biotechnology company focused on developing a new generation of vaccines for animal health. The company's technology platform utilizes fusions of recombinant proteins, a modern approach that avoids attenuated live strains, based on research from the Karolinska Institutet and the Swedish University of Agricultural Sciences. Its lead commercial product is Strangvac®, a vaccine for horses against strangles caused by Streptococcus equi. The development pipeline includes vaccine candidates targeting significant bacterial diseases, such as Streptococcus suis infections in pigs and Staphylococcus aureus-induced mastitis in dairy cows. Intervacc's mission is to improve animal health and welfare while contributing to the reduction of antibiotic use and combating antimicrobial resistance. The company manages sales and distribution through its subsidiary, Nordvacc.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Intervacc AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Intervacc AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Intervacc AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-26 Lennart Johansson Other Other 813,474 691,452.90 SEK
2025-02-21 Lennart Johansson Other Other 324,156 275,532.60 SEK

Peer Companies

ALNYLAM PHARMACEUTICALS, INC. Logo
A biopharmaceutical company developing RNA interference (RNAi) therapeutics.
United States of America
ALNY
Alpha Cognition Inc. Logo
A biopharmaceutical company developing treatments for neurodegenerative diseases.
United States of America
ACOG
Alpha Teknova, Inc. Logo
Manufacturer of critical reagents for the life sciences industry.
United States of America
TKNO
ALTERITY THERAPEUTICS LTD Logo
A clinical-stage biotech developing novel treatments for neurodegenerative diseases.
United States of America
ATHE
Altimmune, Inc. Logo
Clinical-stage biopharma developing peptide therapeutics for obesity and liver diseases.
United States of America
ALT
Alto Neuroscience, Inc. Logo
Develops precision medicines for neuropsychiatric conditions using patient biology.
United States of America
ANRO
ALUMIS INC. Logo
Clinical-stage biopharma developing precision medicines for autoimmune diseases.
United States of America
ALMS
Alvotech Holdings S.A Logo
A biotechnology company developing and manufacturing biosimilar medicines worldwide.
Luxembourg
ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage immuno-oncology company developing therapies to combat cancer.
United States of America
ALXO
Alzamend Neuro, Inc. Logo
Develops treatments for neurodegenerative diseases and psychiatric disorders.
United States of America
ALZN

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.